New combo aims to tame advanced cervical cancer with fewer side effects
NCT ID NCT07143292
First seen Nov 18, 2025 · Last updated May 31, 2026 · Updated 16 times
Summary
This study tests three different doses of the drug famitinib combined with camrelizumab in 120 people with recurrent or metastatic cervical cancer that cannot be cured by standard treatments. The goal is to find a dose that keeps the cancer under control while causing fewer severe side effects. Participants will take famitinib daily and receive camrelizumab infusions, and researchers will monitor how long the cancer stays stable and how well the treatment is tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER RECURRENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.